Equities

Telomir Pharmaceuticals Inc

TELO:NAQ

Telomir Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.95
  • Today's Change-0.05 / -0.83%
  • Shares traded53.36k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 16:56 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Telomir Pharmaceuticals, Inc. is a United States-based company. The Company operates as pre-clinical-stage pharmaceutical company focused on developing TELOMIR-1 small molecule to lengthen the deoxyribonucleic acid’s (DNA) protective telomere caps to affect age reversal. It selectively affects the processes that drive the concentration and accumulation of iron and copper in the serum that affects diseases like hemochromatosis and cancer.

  • Revenue in USD (TTM)0.00
  • Net income in USD-18.74m
  • Incorporated2021
  • Employees1.00
  • Location
    Telomir Pharmaceuticals Inc900 West Platt Street, Suite 200TAMPA 33606United StatesUSA
  • Phone+1 (813) 864-2562
  • Websitehttps://telomirpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
OptiNose Inc75.06m-40.91m128.16m132.00------1.71-0.3479-0.34790.6195-0.28630.63090.79093.50568,621.20-34.39-48.25-199.84-98.9589.9286.96-54.50-131.663.59-0.85371.52---6.9358.6452.58---27.96--
Elutia Inc24.99m-70.10m131.47m54.00------5.26-3.05-2.861.12-2.280.53032.325.08462,722.20-148.77-42.93-1,212.93-79.3442.4643.32-280.53-64.160.6842-0.6561-----49.69-8.71-25.39--12.74--
Global Pharmatech Inc.3.18m-2.24m138.32m217.00--1.02--43.51-0.0964-0.09640.13670.34280.22921.593.5714,649.77-16.44---22.55--46.21---71.75--1.62-9.870.2223--32.43---142.03------
Hongchang International Co Ltd4.65m-292.22k140.08m8.00--3.57--30.13-0.0006-0.00060.00930.07570.16475.028.74---0.8827-7.98-0.9331-10.943.9211.47-5.36-64.883.77--0.2642--3,289.22---42.63------
Eton Pharmaceuticals Inc31.38m-6.69m152.69m30.00--11.30--4.87-0.2596-0.25961.220.52291.008.827.891,046,033.00-21.31-46.22-38.27-58.2059.4872.16-21.31-76.861.28--0.2571--48.90--89.62--26.85--
Biostem Technologies Inc131.44m7.87m158.96m67.0029.178.7819.661.210.33460.33467.311.112.807.413.35--16.78--107.11--94.73--5.98--1.2015.520.2012--------------
Lifecore Biomedical Inc128.26m9.33m160.67m524.0035.0914.058.831.250.14820.23183.831.760.50552.144.26244,774.803.68-5.914.35-8.3332.6331.017.27-19.161.060.23730.6923--24.20-25.46114.5334.47-16.72--
ASP Isotopes Inc2.30m-27.05m177.39m76.00--12.59--77.27-0.628-0.6280.05490.21120.068----30,206.32-71.81---89.44--36.54---1,055.85-----8.110.6748-------229.34------
Telomir Pharmaceuticals Inc0.00-18.74m177.66m1.00--113.33-----0.6855-0.68550.000.05290.00----0.00-467.16---686.91-------------0.92990.00-------1,430.39------
Greenwich Lifesciences Inc0.00-10.22m186.26m3.00--31.52-----0.7942-0.79420.000.44960.00----0.00-112.41-36.43-123.67-38.31------------0.00-------13.63------
Mediwound Ltd20.14m-19.97m189.52m100.00--9.13--9.41-2.16-2.162.181.920.33115.536.55201,410.00-32.83-24.48-49.28-32.9213.2543.27-99.17-38.431.51-3.260.2623---29.4840.6065.73--64.66--
Scilex Holding Co50.83m-171.53m193.71m113.00------3.81-1.40-1.400.4425-1.770.44015.221.55484,123.80-102.93------68.24---233.88--0.1853-3.72----22.90---614.67------
Amylyx Pharmaceuticals Inc298.76m-165.87m196.08m384.00--0.7503--0.6563-2.45-2.454.343.840.76053.6915.91778,026.10-42.22---50.91--84.64---55.52--4.66--0.00--1,612.94--124.84------
Procaps Group SA414.10m52.20m204.21m5.50k3.475.182.930.49320.52090.52094.160.34910.8541.873.3875,290.1810.77--19.01--55.04--12.61--0.9861--0.8829--0.0434--142.18------
Data as of Sep 19 2024. Currency figures normalised to Telomir Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

1.08%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 202478.22k0.26%
Geode Capital Management LLCas of 30 Jun 202466.36k0.22%
The Bank of New York Mellon Corp. (Investment Management)as of 30 Jun 202450.17k0.17%
Suncoast Equity Management LLCas of 30 Jun 202424.39k0.08%
New York State Common Retirement Fundas of 30 Jun 202423.40k0.08%
The Vanguard Group, Inc.as of 30 Jun 202422.98k0.08%
SSgA Funds Management, Inc.as of 30 Jun 202418.13k0.06%
Beaird Harris Wealth Management LLCas of 30 Jun 202414.62k0.05%
Charles Schwab Investment Management, Inc.as of 30 Jun 202410.85k0.04%
BlackRock Investment Management LLCas of 30 Jun 20249.56k0.03%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.